These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
43. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
44. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
45. Transplantation for non-Hodgkin lymphoma. Nademanee A Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947 [TBL] [Abstract][Full Text] [Related]
46. Graft-versus-lymphoma effect after reduced intensity allogeneic hematopoietic stem cell transplantation from HLA-two loci mismatched father in a patient with refractory non-Hodgkin lymphoma. Suminoe A; Matsuzaki A; Koga Y; Hatano M; Hara T; Hara T Turk J Pediatr; 2009; 51(5):500-3. PubMed ID: 20112609 [TBL] [Abstract][Full Text] [Related]
47. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967 [TBL] [Abstract][Full Text] [Related]
48. Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? Freytes CO; Lazarus HM Bone Marrow Transplant; 2009 Nov; 44(9):559-69. PubMed ID: 19701250 [TBL] [Abstract][Full Text] [Related]
50. Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Le Gouill S; Mohty M; Guillaume T; Gastinne T; Moreau P Semin Hematol; 2011 Jul; 48(3):227-39. PubMed ID: 21782065 [TBL] [Abstract][Full Text] [Related]
57. Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Niederwieser D; Dölken G Ann Hematol; 2014 Sep; 93(9):1587-97. PubMed ID: 24782119 [TBL] [Abstract][Full Text] [Related]
58. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Verdonck LF Leuk Lymphoma; 1999 Jun; 34(1-2):129-36. PubMed ID: 10350340 [TBL] [Abstract][Full Text] [Related]